Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury

Circulation Research

Volumn 109, Issue 12, 2011, Pages 1396-1400

  Ladage, Dennis ^a   Tilemann, Lisa ^a   Ishikawa, Kiyotake ^a   Correll, Robert N ^b   Kawase, Yoshiaki ^a   Houser, Steven R ^c   Molkentin, Jeffery D ^b,d   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Contractility; Heart failure; PKC; Signaling

Indexed keywords

PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; RUBOXISTAURIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; CARDIAC OUTPUT; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HEART; HEART FAILURE; INDOLES; MALEIMIDES; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PYRROLES; STROKE VOLUME; SWINE;

EID: 84856087050     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.255687     Document Type: Article

References (24)

1. Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu Rev Pharmacol Toxicol. 2008;48:569-599. (Pubitemid 351738164)
2. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev. 2008;88:1341-1378.
3. Pass JM, Gao J, Jones WK, Wead WB, Wu X, Zhang J, Baines CP, Bolli R, Zheng YT, Joshua IG, Ping P. Enhanced PKC beta II translocation and PKC beta II-RACK1 interactions in PKC epsilon-induced heart failure: a role for RACK1. Am J Physiol Heart Circ Physiol. 2001;281:H2500-H2510.
4. Ping P, Zhang J, Qiu Y, Tang XL, Manchikalapudi S, Cao X, Bolli R. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res. 1997;81:404-414. (Pubitemid 27362528)
5. Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, Kimball TF, Hewett TE, Dorn GW II, Koch WJ, Molkentin JD. Pharmacological-and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006;114:574-582. (Pubitemid 44199647)
6. De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun. NH2-terminal kinase activation in the heart: cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem. 2000;275:13571-13579. (Pubitemid 30257424)
7. Gu X, Bishop SP. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res. 1994;75:926-931. (Pubitemid 24323527)
8. Jalili T, Takeishi Y, Song G, Ball NA, Howles G, Walsh RA. PKC translocation without changes in Galphaq and PLC-beta protein abundance in cardiac hypertrophy and failure. Am J Physiol. 1999;277:H2298-H2304. (Pubitemid 30048150)
9. Takeishi Y, Bhagwat A, Ball NA, Kirkpatrick DL, Periasamy M, Walsh RA. Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol. 1999;276:H53-H62. (Pubitemid 29065622)
10. Bayer AL, Heidkamp MC, Patel N, Porter M, Engman S, Samarel AM. Alterations in protein kinase C isoenzyme expression and autophosphorylation during progression of pressure overload-induced left ventricular hypertrophy. Mol Cell Biochem. 2003;242:145-152. (Pubitemid 36240540)
11. Wang J, Liu X, Sentex E, Takeda N, Dhalla NS. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284:H2277-H2287. (Pubitemid 36622442)
12. Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ. Increased protein kinase C activity and expression of calcium-sensitive isoforms in the failing human heart. Circulation. 1999;99:384-391. (Pubitemid 29051264)
13. Simonis G, Briem SK, Schoen SP, Bock M, Marquetant R, Strasser RH. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol Cell Biochem. 2007;305:103-111. (Pubitemid 47517173)
14. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Iodi B, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD. PKCa regulates cardiac contractility and propensity towards heart failure. Nat Med. 2004;10:248-254. (Pubitemid 38667614)
15. Hahn HS, Marreez Y, Odley A, Sterbling A, Yussman MG, Hilty KC, Bodi I, Liggett SB, Schwartz A, Dorn GW II. Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circ Res. 2003;93:1111-1119. (Pubitemid 37485043)
16. Hambleton M, York A, Sargent MA, Kaiser RA, Lorenz JN, Robbins J, Molkentin JD. Inducible and myocyte-specific inhibition of PKCalpha enhances cardiac contractility and protects against infarction-induced heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H3768-H3771. (Pubitemid 350230925)
17. Liu Q, Chen X, Macdonnell SM, Kranias EG, Lorenz JN, Leitges M, Houser SR, Molkentin JD. Protein kinase Calpha, but not PKCbeta or PKCgamma, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res. 2009;105:194-200.
18. Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009;119:3797-3806.
19. Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, Itescu S, Krum H, Gilbert RE. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol. 2005;39:213-221. (Pubitemid 40995010)
20. Kong L, Andrassy M, Chang JS, Huang C, Asai T, Szabolcs MJ, Homma S, Liu R, Zou YS, Leitges M, Yan SD, Ramasamy R, Schmidt AM, Yan SF. PKCbeta modulates ischemia-reperfusion injury in the heart. Am J Physiol Heart Circ Physiol. 2008;294:H1862-H1870. (Pubitemid 351492503)
21. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, Thai K, Krum H, Gilbert RE. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail. 2009;2:129-137.
22. The PKC-DRS Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol. 2007;125:318-324.
23. Liu Q, Molkentin JD. Protein kinase Cα as a heart failure therapeutic target. J Mol Cell Cardiol. 2011;51:474-478.
24. Wise S, Yuen E, Chan C, Poo Y-K, Teng L, Lau T, Voelker J. Effects of chronic renal failure on the pharmacokinetics of ruboxistaurine and its active metabolite 338522. Clin Pharmacokinet. 2006;45:297-303. (Pubitemid 43327494)